Peptide Reference Desk
KPV vs alpha-MSH: a three-residue fragment cannot inherit the whole hormone’s evidence
KPV corresponds to the C-terminal Lys-Pro-Val motif of alpha-MSH, but fragment identity does not transfer receptor pharmacology or biological evidence wholesale.
The sequence relationship is real—and limited
KPV is the tripeptide Lys-Pro-Val, corresponding to the C-terminal residues of alpha-melanocyte-stimulating hormone (alpha-MSH). This makes “alpha-MSH fragment” a useful provenance label. It does not mean KPV reproduces every receptor interaction or physiological effect of the full 13-residue hormone.
Fragment claims require fragment data
Many summaries begin with alpha-MSH biology and then move directly to KPV conclusions. A rigorous review asks whether the cited experiment tested KPV, full-length alpha-MSH, another melanocortin analogue or a mixture.
| Evidence field | Required entry |
|---|---|
| Test article | Exact sequence and terminal form |
| Mechanism | Directly measured receptor/pathway, not presumed inheritance |
| Model | Cell type, species, inflammatory stimulus and controls |
| Endpoint | Assay method, timing and prespecified analysis |
Short peptides present analytical traps
For a tripeptide, conventional UV detection can be insensitive and chromatographic retention may be weak. LC-MS, charged-aerosol detection, amino-acid analysis or other justified methods may be needed. Counterion, water and net content can materially affect a milligram label.
Translation remains a separate question
Cellular or animal anti-inflammatory findings can motivate research, but they do not establish human efficacy, dosing or safety. The professional summary should preserve that boundary instead of using “derived from a natural hormone” as a clinical shortcut.
Verify with primary records
Use the primary paper, current regulator label or lot-linked analytical file for the claim it supports. A search result is a route to evidence, not the evidence itself.